Navigation Links
Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Date:9/28/2007

rysm, or "bulging" of the major artery which arises from the heart, is a serious condition prone to rupture and sudden death. According to the Society for Vascular Surgery, less than half of all patients who experience a rupture of a thoracic aortic die before reaching the hospital, making it the 13th leading cause of death in the U.S. Furthermore, studies report that emergent, open surgical repair of a ruptured thoracic aneurysm carries a 25 to 50 percent risk of death. ELGs, which are metal stents covered by a fabric graft material, offer a lower-risk alternative to open surgical repair. The device is delivered under X-ray guidance via a catheter passed through an artery near the groin. The ELG is then positioned and expanded within the aorta at the site of the problem, restoring blood flow, providing significant pain relief and reducing the risk of rupture. Depending on their general condition, patients typically return home within a few days.

"It is evident that ELGs represent an important means of treating thoracic aortic pathologies," said Venkatesh G. Ramaiah, M.D., study co-author and director of Peripheral Vascular and Endovascular Research at the Arizona Heart Institute. "To date, this is the largest published series of patients treated with thoracic ELGs for a variety of thoracic aortic pathologies. After more than 500 cases performed at the Arizona Heart Institute, complication rates, including death, compare favorably with open surgical repair, suggesting that endoluminal grafting is a favorable alternative in the treatment of thoracic aortic pathologies," said Ramaiah.

"We are very pleased with the results from this important study which further supports the movement toward minimally invasive management of aortic disease," said Edward B. Diethrich, M.D., medical director, founder of the Arizona Heart Institute and study author. "Since the early 1990s, we have pioneered a multitude of new technologies, treatments and therapies for cardiovasc
'/>"/>

SOURCE The Arizona Heart Institute
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... Care Conference in Boston.   The live presentation ... Time / 8:20 a.m. Pacific Time.  The presentation will be ... http://www.neurocrine.com . If you are unable ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... Pharmasset, Inc.,(Nasdaq: VRUS ) has commenced ... in,combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) ... hepatitis C,virus (HCV) genotype 1. R7128 is a ... inhibitor of HCV that is being developed,through Pharmasset,s ...
... EDMONTON, Alberta, Oct. 2 Medical Services,International Inc. (Pink ... its VScan Dengue Fever Kit is increasing. Dengue Fever ... of the worst,outbreaks in decades causing agonizing joint pain ... so far this year. This year so far ...
Cached Medicine Technology:Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 2Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 3Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 4Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 5Demand for VScan Dengue Fever Test Kits Increases 2
(Date:5/25/2013)... On May 25, Voices Against Brain Cancer, ... comments on a new study by the Max Planck ... plasma into brain cancer treatment may help when dealing ... Science Daily article, physicists from the Max Planck ... the “synergistic effect of cold atmospheric plasma -- a ...
(Date:5/25/2013)... May 25, 2013 Dr. Farooq Ashraf, ... clinic in Dubai, has announced his practice’s adoption of ... the only FDA-cleared femtosecond laser proven with more than ... and precision of LASIK. , “We are happy to ... Femtosecond Laser at our Dubai LASIK practice,” Ashraf said ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The Slim Weight ... effectiveness and results. This is due to the highly sought ... patches. Slim weight patch offers an extra 2 months supply ... fitness goals and get the body you desire faster than ... Official Website , With Slim weight patch consumers can ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 For ... than finals week. Increasingly, they are turning to ... awake and study. For more on this, go ... drug treatment facility, warns that students who pick ... are at risk for developing a physical and ...
(Date:5/25/2013)... Richmond, Virginia (PRWEB) May 25, 2013 ... bracelet that relieves pain in seconds for arthritis, tendinitis ... innovator in alternative pain relief products announced a ... seconds. The magnetic bracelet for pain relief is demonstrated ... for pain uses 5400 Gauss magnets and has customers ...
Breaking Medicine News(10 mins):Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2
... to relieve stress, a common cause of heart ... ... us think,of love and Valentine,s Day. This February, which also is National Heart,Awareness ... your heart. A healthy heart can be attained in a variety,of ways that ...
... PORTLAND, Ore. An Oregon Health & Science University Cancer ... the ability to predict if a mans prostate cancer is ... In order to make this discovery, researchers examined prostate cancer ... cancer patients. The researchers found that men whose tumors showed ...
... course of the presidential nomination campaign, some candidates health ... the phrase socialized medicine has been used to attack ... poll by the Harvard Opinion Research Program at the ... finds that Americans are split on whether a socialized ...
... National Board, KNOXVILLE, Tenn., Feb. 14 ... of Stacy Goldsholl, MD, as an,officer of its ... Medicine, is serving her second consecutive term as ... the premier medical society that,represents hospitalists. Hospital medicine ...
... (Nasdaq: DATA ), a technology company focused ... today reported that it will be,presenting at the ... at the Ritz Carlton in Laguna Niguel, California, ... on Wednesday afternoon,February 20th at 2:30 P.M., Pacific ...
... researchers from Europe and North America were given important ... national boundaries at a two-day training course in Croydon, ... Foundation as part of its Pan-European Clinical Trials (ECT) ... trials with a specific focus on the Euramos trial ...
Cached Medicine News:Health News:Healthy Heart, Healthy Home 2Health News:OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence 2Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:Stacy Goldsholl, MD, Re-elected to Board of Society of Hospital Medicine 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 3Health News:ESF's EMRC strengthens training course on clinical trials management 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: